title: Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy.
abstract: Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cellsin vivo. Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.
authors.affiliation: Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University , Changchun, China.
authors.forename: Jintong
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University , Changchun, China.
authors.forename: Yinghua
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University , Changchun, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Chu
authors.affiliation: Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic , Cleveland, OH, USA.
authors.forename: Yong
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University , Changchun, China.
authors.forename: Siqing
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: Yi
keywords: Antitumor immunity; Dectin-1; Th9; Vaccine; dentritic cells